DE4211745A1 - Use of propolis as antiinflammatory agent - to inhibit release of inflammation mediators from inflammatoric cells e.g. in treatment of lung diseases - Google Patents

Use of propolis as antiinflammatory agent - to inhibit release of inflammation mediators from inflammatoric cells e.g. in treatment of lung diseases

Info

Publication number
DE4211745A1
DE4211745A1 DE4211745A DE4211745A DE4211745A1 DE 4211745 A1 DE4211745 A1 DE 4211745A1 DE 4211745 A DE4211745 A DE 4211745A DE 4211745 A DE4211745 A DE 4211745A DE 4211745 A1 DE4211745 A1 DE 4211745A1
Authority
DE
Germany
Prior art keywords
propolis
cells
inflammatoric
treatment
inflammation mediators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE4211745A
Other languages
German (de)
Inventor
Klaus Dr Winsel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOERNER GmbH
Original Assignee
BOERNER GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOERNER GmbH filed Critical BOERNER GmbH
Priority to DE4211745A priority Critical patent/DE4211745A1/en
Publication of DE4211745A1 publication Critical patent/DE4211745A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Insects & Arthropods (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Animal Husbandry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Use of propolis (bee glue) and/or fractions of this to inhibit the release of inflammation mediators such as arachidonic acid metabolites, reactive oxygen metabolites, histamine and interleucin, from inflammatoric cells. USE/ADVANTAGE - Propolis is a natural substnace collected by bees and exhibits a high antiinflammatory activity in small doses, esp. against arachidonate-, allergen- and xanthin/xanthinooxidase-induced brochoconstriction e.g. in asthma and bronchitis, without causing unwanted side effects (osteoporosis, glaucoma, cataracts, etc) sometimes found when using glucoroticoids as anti-inflammatory and anti-allergenic agents

Description

Es ist bekannt, daß Entzündungen verschiedener Genese und die damit verbundenen Erkrankungen durch die Freisetzung von Me­ diatoren aus inflamatorischen Zellen, wie humanen neutrophi­ len und basophilen Granulozyten, Makrophagen, Monozyten und Mastzellen, hervorgerufen werden. Solche Mediatoren sind vor­ zugsweise Arachidonsäure-Derivate, reaktive Sauerstoffmetabo­ lite und Histamin.It is known that inflammation of various origins and related diseases due to the release of Me Inflammatory cell diets such as human neutrophi len and basophilic granulocytes, macrophages, monocytes and Mast cells. Such mediators are in front preferably arachidonic acid derivatives, reactive oxygen metabolism lite and histamine.

Zur Inhibition der Bildung dieser Mediatoren werden besonders bei Lungenerkrankungen (z. B. Asthma bronchiale, Sarkoidose, Lungenfibrose) Glukokortikoide eingesetzt. Die Glokokortikoi­ de haben zwar ein breites antiinflamatorisches und antialler­ gisches Wirkungsspektrum, ihre Anwendung ist aber durch starke Nebenwirkungen eingeschränkt. Als Nebenwirkungen sind u. a. bekannt: Osteoporose, Glaukom, Katarakt, Vollmondgesicht, Stammfettsucht, verminderte Glokosetoleranz, Hypertonie.To inhibit the formation of these mediators are special for lung diseases (e.g. bronchial asthma, sarcoid, Pulmonary fibrosis) used glucocorticoids. The Glokokortikoi de have a broad anti-inflammatory and antialler spectrum of effectiveness, but their application is strong Side effects limited. As side effects are u. a. known: osteoporosis, glaucoma, cataract, full moon face, Stem obesity, reduced glucose tolerance, hypertension.

Der Erfindung liegt die Aufgabe zugrunde, ein Mittel vorzuse­ hen, das die erwähnten Nebenwirkungen nicht aufweist.The object of the invention is to provide a means hen that does not have the side effects mentioned.

Die Lösung dieser Aufgabe besteht in der Verwendung von Pro­ polis und/oder seinen Fraktionen zur Hemmung der Freisetzung von Entzündungsmediatoren, wie Arachidonsäuremetabolite, reaktive Sauerstoffmetabolite, Histamin und Interleukin aus inflamatorischen Zellen.The solution to this problem is to use Pro polis and / or its fractions to inhibit release inflammatory mediators, such as arachidonic acid metabolites, reactive oxygen metabolites, histamine and interleukin inflammatory cells.

Als Arachidonsäuremetabolite kommen beispielsweise in Frage: Leukotrien B4, Leukotrien C4, Leukotrien D4, 5-Hydroxyeicosatetraensäure, Prostaglandin F2 α, Prostaglan­ din D2.Examples of possible arachidonic acid metabolites are: Leukotriene B4, leukotriene C4, leukotriene D4, 5-Hydroxyicosatetraenoic acid, prostaglandin F2α, prostaglan din D2.

Propolis ist ein von Bienen gesammelter Naturstoff. Es hat sich gezeigt, daß dieser die erwähnten Eigenschaften besitzt, aber frei von den störenden, oben erwähnten Nebenwirkungen ist. Hinzu kommt, daß man mit geringeren Konzentrationen als bei den Glukokortikoiden größere Wirkungen erzielt.Propolis is a natural substance collected by bees. It has it has been shown that this has the properties mentioned, but free from the annoying side effects mentioned above is. In addition, one with lower concentrations than achieved greater effects on glucocorticoids.

Die gemäß Anspruch 1 vorgeschlagene Verwendung führt insbe­ sondere zur Hemmung der Arachidonat-, Allergen-, Xanthin/Xanthinoxidase-induzierten Bronchokonstriktion.The use proposed according to claim 1 leads in particular especially for the inhibition of arachidonate, allergen, Xanthine / xanthine oxidase-induced bronchoconstriction.

Claims (2)

1. Verwendung von Propolis und/oder seinen Fraktionen zur Hemmung der Freisetzung von Entzündungsmediatoren, wie Ara­ chidonsäuremetabolite, reaktive Sauerstoffmetabolite, Hist­ amin, Interleukin, aus inflamatorsischen Zellen.1. Use of propolis and / or its fractions Inhibiting the release of inflammatory mediators, such as macaw chidonic acid metabolites, reactive oxygen metabolites, hist amine, interleukin, from inflammatory cells. 2. Verwendung nach Anspruch 1 zur Hemmung der Arachidonat-, Allergen-, Xanthin/Xanthinoxidase-induzierten Bronchokon­ striktion2. Use according to claim 1 for inhibiting the arachidonate, Allergen, xanthine / xanthine oxidase-induced bronchocone strict
DE4211745A 1992-04-03 1992-04-03 Use of propolis as antiinflammatory agent - to inhibit release of inflammation mediators from inflammatoric cells e.g. in treatment of lung diseases Ceased DE4211745A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE4211745A DE4211745A1 (en) 1992-04-03 1992-04-03 Use of propolis as antiinflammatory agent - to inhibit release of inflammation mediators from inflammatoric cells e.g. in treatment of lung diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4211745A DE4211745A1 (en) 1992-04-03 1992-04-03 Use of propolis as antiinflammatory agent - to inhibit release of inflammation mediators from inflammatoric cells e.g. in treatment of lung diseases

Publications (1)

Publication Number Publication Date
DE4211745A1 true DE4211745A1 (en) 1993-10-07

Family

ID=6456351

Family Applications (1)

Application Number Title Priority Date Filing Date
DE4211745A Ceased DE4211745A1 (en) 1992-04-03 1992-04-03 Use of propolis as antiinflammatory agent - to inhibit release of inflammation mediators from inflammatoric cells e.g. in treatment of lung diseases

Country Status (1)

Country Link
DE (1) DE4211745A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19513540A1 (en) * 1995-04-10 1996-10-17 Friesland Brands Bv Use of propolis, administered non-topically, opt. in combination with casein
AT403546B (en) * 1996-02-22 1998-03-25 Kullnig Barbara Anti-inflammatory, onion-containing ointment
US5889049A (en) * 1993-06-13 1999-03-30 Juergens; Uwe R. Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators
ES2148113A1 (en) * 1999-03-09 2000-10-01 Bioserum Lab S L Respiration aid based on atomized plant extracts consists of a mixture incorporating plantain, eucalyptus, thyme pine bud and elder extracts, dissolved in water with stirring
WO2000074693A2 (en) * 1999-06-09 2000-12-14 Bondco 897 Limited Immunity generation
WO2001001995A2 (en) * 1999-07-06 2001-01-11 Nutricology, Inc. Method for treatment of asthma syndrome
WO2014060533A1 (en) * 2012-10-17 2014-04-24 Montero Gida Sanayi Ve Ticaret A.S. Herbal formulations
CN104353035A (en) * 2014-10-27 2015-02-18 青岛祥翔生物医药科技有限公司 Traditional Chinese medicine for treating deficiency-cold type consumptive lung disease
US20150290268A1 (en) * 2012-10-17 2015-10-15 Montero Gida Sanayi Ve Ticaret A.S. Formulations comprising herbal extracts
US9907824B2 (en) 2012-10-18 2018-03-06 Montero Gida Sanayi Ve Ticaret A.S. Stable formulations
US10111925B2 (en) 2012-10-17 2018-10-30 Montero Gida Sanayi Ve Ticaret A.S. Formulations comprising plant extracts

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Chem. Abstr. 114, 162818x (1991) *
Derwent 87, 161643/23 *
Derwent 89, 107789/15 *
Derwent 90, 214218/28 *
Dirk *
Propolis BTV Berlin 1987, S. 76 u. 79 *
ROHWEDDER *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889049A (en) * 1993-06-13 1999-03-30 Juergens; Uwe R. Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators
DE19513540A1 (en) * 1995-04-10 1996-10-17 Friesland Brands Bv Use of propolis, administered non-topically, opt. in combination with casein
AT403546B (en) * 1996-02-22 1998-03-25 Kullnig Barbara Anti-inflammatory, onion-containing ointment
ES2148113A1 (en) * 1999-03-09 2000-10-01 Bioserum Lab S L Respiration aid based on atomized plant extracts consists of a mixture incorporating plantain, eucalyptus, thyme pine bud and elder extracts, dissolved in water with stirring
GB2368016A (en) * 1999-06-09 2002-04-24 Christopher Jeremy Leonard Immunity generation
WO2000074693A3 (en) * 1999-06-09 2001-06-28 Christopher Jeremy Leonard Immunity generation
WO2000074693A2 (en) * 1999-06-09 2000-12-14 Bondco 897 Limited Immunity generation
GB2368016B (en) * 1999-06-09 2004-09-01 Christopher Jeremy Leonard Immunity generation
WO2001001995A2 (en) * 1999-07-06 2001-01-11 Nutricology, Inc. Method for treatment of asthma syndrome
WO2001001995A3 (en) * 1999-07-06 2001-11-15 Nutricology Inc Method for treatment of asthma syndrome
WO2014060533A1 (en) * 2012-10-17 2014-04-24 Montero Gida Sanayi Ve Ticaret A.S. Herbal formulations
US20150290268A1 (en) * 2012-10-17 2015-10-15 Montero Gida Sanayi Ve Ticaret A.S. Formulations comprising herbal extracts
US9913869B2 (en) 2012-10-17 2018-03-13 Montero Gida Sanayi Ve Ticaret A.S. Formulations comprising herbal extracts
US10111925B2 (en) 2012-10-17 2018-10-30 Montero Gida Sanayi Ve Ticaret A.S. Formulations comprising plant extracts
US10111912B2 (en) 2012-10-17 2018-10-30 Montero Gida Sanayi Ve Ticaret A.S. Herbal formulations
US9907824B2 (en) 2012-10-18 2018-03-06 Montero Gida Sanayi Ve Ticaret A.S. Stable formulations
CN104353035A (en) * 2014-10-27 2015-02-18 青岛祥翔生物医药科技有限公司 Traditional Chinese medicine for treating deficiency-cold type consumptive lung disease

Similar Documents

Publication Publication Date Title
DE4211745A1 (en) Use of propolis as antiinflammatory agent - to inhibit release of inflammation mediators from inflammatoric cells e.g. in treatment of lung diseases
Franz Wirtschaftspolitische Beratung: Reminiszenzen und Reflexionen
EP0297457A2 (en) Cosmetic product
Al‐Qarawi et al. Effect of freeze dried extract of Olea europaea on the pituitary–thyroid axis in rats
DE19850516A1 (en) Hair tonic composition
EP2670382B1 (en) Cosmetic use
DD152473A5 (en) HAIR-RELATED AGENTS AND METHOD FOR THEIR MANUFACTURE
DE2941784C2 (en) Process for the preparation of a hair lotion against hair loss
DE69727239T2 (en) UP TO 1% FLAVONOID EXTRACT BY GINGKO BILOBA WITH CERAMIDES FOR ORAL HYGIENE AND COMPOSITIONS THEREOF
JP5976544B2 (en) Method for producing tea water, tea water obtained thereby, cosmetic composition containing the tea water, food composition, and pharmaceutical composition
EP0076987A2 (en) Cosmetic agent
Bruzek et al. Über eruptionsartige Fackeln bei Filamentaufstiegen. Mit 5 Textabbildungen
Grolle Trocholejeunea fossil in Europa
Brandt Stadienspezifische Korrelation zwischen der Aktivität von Photosystem lund Photosystem II und der molekularen Zusammensetzung von photosynthetisch aktiven Partikeln aus synchronisierter Euglena gracilis, Stamm Z
EP2036537A1 (en) Macro algae extract
Mautner et al. “Ist Fortzusetzen”: Zu Goethes Gedicht auf Schillers Schaedel
Fischer Linguistik für Sprachtherapeuten
DE4319554A1 (en) Use of essential oils for suppressing the release of arachidonic acid
Korfsmeier Epitheliale Hauttumoren und gesundes Hautepithel in der Gewebekultur
DE4130915A1 (en) Topical compsn. contg. steroid or tri:terpenoid glycoside - and sphingolipid, opt. also steroid hormone, as moisture retaining agent for scalp and for treating rough skin
DE696521C (en) Process for obtaining substances that lower blood sugar
Dührsen Von der narzißtischen Illusion zum Dialog. Phasen im Verlauf ambulanter tiefenpsychologisch fundierter Psychotherapien mit Psychosekranken
Siegel Der Gemeinnützige Verein Kirchlichen Zwecks: Verfahren, Voraussetzungen und Besonderheiten innerhalb des deutschen Steuerrechts
Oehler et al. Antithrombin III-Veränderungen nach Herzinfarkt
Siebenmann Die Wirkung von Desoxycorticosteron-Acetat (DCA), Ascorbinsäure und Cortison (Compound E) auf die Formalinarthritis der Ratte

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8131 Rejection